NASDAQ:SYBXSynlogic Stock Price, Forecast & News

Synlogic's stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SYBX shares have increased by 63.0% and is now trading at $2.51.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Synlogic.

Synlogic is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Synlogic.

Synlogic Inc (NASDAQ:SYBX) posted its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.46) by $0.02. Synlogic had a negative net margin of 2,761.83% and a negative return on equity of 36.85%.
View Synlogic's earnings history.

Shares of Synlogic reverse split on Monday, August 28th 2017. The 1-7 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 25th 2017. An investor that had 100 shares of Synlogic stock prior to the reverse split would have 14 shares after the split.

5 equities research analysts have issued 1-year price targets for Synlogic's stock. Their forecasts range from $2.00 to $13.00. On average, they expect Synlogic's share price to reach $7.33 in the next twelve months. This suggests a possible upside of 192.2% from the stock's current price.
View analysts' price targets for Synlogic.

Press coverage about SYBX stock has been trending somewhat negative on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Synlogic earned a news sentiment score of -1.3 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about Synlogic.

Synlogic saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 353,100 shares, an increase of 7.2% from the July 15th total of 329,400 shares. Based on an average daily volume of 338,600 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.9% of the shares of the stock are sold short.
View Synlogic's Short Interest.

Some companies that are related to Synlogic include CytomX Therapeutics (CTMX), Geron (GERN), REDHILL BIOPHAR/S (RDHL), Pivot Pharmaceuticals (PVOTF), Aeglea Bio Therapeutics (AGLE), MEI Pharma (MEIP), Immunic (IMUX), Concert Pharmaceuticals (CNCE), OptiNose (OPTN), Arbutus Biopharma (ABUS), Tiziana Life Sciences (TLSA), Avadel Pharmaceuticals (AVDL), Affimed (AFMD), Osmotica Pharmaceuticals (OSMT) and Bicycle Therapeutics (BCYC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Verastem (VSTM) and Rigel Pharmaceuticals (RIGL).

Synlogic trades on the NASDAQ under the ticker symbol "SYBX."

Synlogic's stock is owned by many different retail and institutional investors. Top institutional investors include Bank of New York Mellon Corp (0.25%), Verition Fund Management LLC (0.22%) and Goldman Sachs Group Inc. (0.16%). Company insiders that own Synlogic stock include Paul Francis Miller and Richard P Shea.
View institutional ownership trends for Synlogic.

SYBX stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp.
View insider buying and selling activity for Synlogic.

SYBX stock was acquired by a variety of institutional investors in the last quarter, including Verition Fund Management LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for Synlogic.

Shares of SYBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SYBX stock can currently be purchased for approximately $2.51.

Synlogic has a market capitalization of $85.76 million and generates $2.22 million in revenue each year. The biotechnology company earns $-51,370,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Synlogic employs 74 workers across the globe.

The official website for Synlogic is www.synlogictx.com.

Synlogic's mailing address is 301 Binney St. Suite 402, Cambridge MA, 02142. The biotechnology company can be reached via phone at 617-401-9975 or via email at [email protected]